Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study

Two influenza vaccines are licensed in the U.S. exclusively for the 65 years and older population: a trivalent inactivated high-dose influenza vaccine (HD-IIV3) and a trivalent inactivated adjuvanted influenza vaccine (aIIV3). In a recent publication, we estimated a relative vaccine effectiveness (r...

Full description

Bibliographic Details
Published in:Vaccines
Main Authors: Robertus van Aalst, Stefan Gravenstein, Vincent Mor, Salaheddin M. Mahmud, Jan Wilschut, Maarten Postma, Ayman Chit
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Subjects:
high-dose
adjuvanted
aIIV3
HD-IIV3
influenza vaccine
economic assessment
Online Access:https://www.mdpi.com/2076-393X/9/10/1065

Internet

https://www.mdpi.com/2076-393X/9/10/1065

Similar Items